Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Comment by pericles1on Nov 07, 2014 2:16pm

73 Views

Post# 23107789

RE:Hold on to your hat!

Looking at the two cases on the poster is seems that something very complex and very important is going on. It seems the immune response is strong but takes a long time to take down the cancer. I have no doubt that we can improve on this with multiple injection sites. Maybe the injections need to occur at even longer intervals, how persistant will the effects be? Also with the two case studies did you notice that our star Allan from national geographic was not mentioned. The news is good enough no reason to pile on, that's what you get with men of science! AF SHOVE IT!

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?